Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Prospective, Single-arm Study Assessing the Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

NCT07246564 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT07246564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07246564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Prospective, Single-arm Study Assessing the Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
Lead sponsor
UCB Biopharma SRL
Phase
Phase 4
Overall status
Recruiting
Start date
December 1, 2025
Completion date
October 15, 2027
Enrollment
40 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

myasthenia gravis